Nucleic acid ligands to CD40ligand
First Claim
Patent Images
1. A nucleic acid ligand to CD40ligand identified according to a method comprising:
- a) preparing a candidate mixture of nucleic acids;
b) contacting the candidate mixture of nucleic acids with CD40ligand, wherein nucleic acids having an increased affinity to CD40ligand relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and
d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to CD40ligand, whereby a nucleic acid ligand of CD40ligand may be identified.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods are provided for generating nucleic acid ligands of CD40ligand. The methods of the invention use the SELEX method for the isolation of nucleic acid ligands. The invention also includes nucleic acid ligands to CD40ligand, and methods and compositions for the treatment and diagnosis of disease using the nucleic acid ligands.
-
Citations
14 Claims
-
1. A nucleic acid ligand to CD40ligand identified according to a method comprising:
-
a) preparing a candidate mixture of nucleic acids;
b) contacting the candidate mixture of nucleic acids with CD40ligand, wherein nucleic acids having an increased affinity to CD40ligand relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and
d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to CD40ligand, whereby a nucleic acid ligand of CD40ligand may be identified. - View Dependent Claims (2, 3, 4, 5, 6, 7, 10, 11, 12)
-
-
8. A purified and non-naturally occuring RNA ligand to CD40ligand wherein said ligand is selected from the group consisting of SEQ. ID. NO. 18, 20 and 26.
-
9. A purified and non-naturally occurring nucleic acid ligand to CD40ligand.
- 13. A method of inhibiting interaction of CD40ligand and CD40 positive cells in vitro comprising contacting the CD40ligand with a CD40ligand nucleic acid ligand.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeGilead Sciences Inc.
-
Original AssigneeNeXstar Pharmaceuticals, Inc. (Gilead Sciences Inc.)
-
InventorsKorman, Alan J., Gold, Larry
-
Primary Examiner(s)Elliott, George C.
-
Assistant Examiner(s)LACOURCIERE, KAREN A
-
Application NumberUS09/364,380Time in Patent Office530 DaysField of Search435/6, 435/375, 435/325, 435/440, 536/23.1, 536/24.3, 536/24.33, 514/44US Class Current435/6.11CPC Class CodesA61K 48/00 Medicinal preparations cont...A61P 37/06 Immunosuppressants, e.g. dr...A61P 41/00 Drugs used in surgical meth...A61P 43/00 Drugs for specific purposes...A61P 9/10 for treating ischaemic or a...C12N 15/1138 against receptors or cell s...
